What is HC Wainwright’s Estimate for CORT FY2030 Earnings?

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities researchers at HC Wainwright cut their FY2030 earnings per share (EPS) estimates for Corcept Therapeutics in a report issued on Wednesday, February 25th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings per share of $7.19 for the year, down from their previous forecast of $7.74. HC Wainwright currently has a “Buy” rating and a $67.00 price target on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.13). Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The business had revenue of $202.13 million during the quarter, compared to the consensus estimate of $254.94 million. During the same quarter in the previous year, the business posted $0.26 earnings per share. The firm’s revenue was up 11.1% on a year-over-year basis.

Several other analysts have also recently issued reports on CORT. Zacks Research cut Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Truist Financial set a $50.00 price target on shares of Corcept Therapeutics in a research note on Wednesday, December 31st. Canaccord Genuity Group boosted their target price on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, January 23rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday, December 29th. Finally, UBS Group initiated coverage on Corcept Therapeutics in a research report on Tuesday, December 16th. They set a “neutral” rating and a $95.00 price objective on the stock. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Corcept Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $77.17.

Corcept Therapeutics Stock Down 1.2%

Shares of CORT opened at $35.78 on Thursday. The business’s 50 day moving average is $45.37 and its 200 day moving average is $66.02. The company has a market capitalization of $3.81 billion, a PE ratio of 43.63 and a beta of 0.25. Corcept Therapeutics has a 12-month low of $28.66 and a 12-month high of $117.33. The company has a current ratio of 2.92, a quick ratio of 3.07 and a debt-to-equity ratio of 0.01.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, insider Joseph Douglas Lyon sold 5,000 shares of the company’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $79.53, for a total transaction of $397,650.00. Following the completion of the sale, the insider owned 10,277 shares in the company, valued at $817,329.81. This represents a 32.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider William Guyer sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $40.87, for a total transaction of $817,400.00. Following the transaction, the insider owned 1,235 shares of the company’s stock, valued at approximately $50,474.45. This trade represents a 94.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 125,000 shares of company stock worth $8,301,450 over the last quarter. 20.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of CORT. AQR Capital Management LLC boosted its holdings in Corcept Therapeutics by 546.9% in the third quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company’s stock valued at $125,264,000 after purchasing an additional 1,274,215 shares during the last quarter. Norges Bank acquired a new position in shares of Corcept Therapeutics during the second quarter valued at approximately $72,048,000. Epoch Investment Partners Inc. purchased a new stake in shares of Corcept Therapeutics during the second quarter worth $56,181,000. Geode Capital Management LLC raised its holdings in Corcept Therapeutics by 38.0% in the 4th quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock valued at $92,892,000 after acquiring an additional 734,646 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Corcept Therapeutics by 223.4% in the third quarter. JPMorgan Chase & Co. now owns 849,864 shares of the biotechnology company’s stock valued at $70,632,000 after purchasing an additional 587,053 shares during the last quarter. 93.61% of the stock is owned by institutional investors and hedge funds.

Corcept Therapeutics News Summary

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Management reiterated a large 2026 revenue opportunity — $900M–$1B — as relacorilant’s oncology approval approaches, supporting upside if approval and commercial traction materialize. Article Title
• Neutral Sentiment: Analyst note: HC Wainwright trimmed a long‑term FY2030 EPS forecast (from $7.74 to $7.19) but maintained a Buy rating and $67 target, signaling continued analyst confidence in the longer‑term story despite near‑term misses.
• Negative Sentiment: Q4 results missed consensus — EPS and revenue came in below expectations (Q4 EPS ~$0.20; revenue ~$202M vs. higher estimates), prompting investor concern about growth momentum and guidance. Article Title
• Negative Sentiment: Multiple law firms have announced securities‑fraud class‑action filings and are soliciting lead‑plaintiff applicants (class period cited Oct 31, 2024–Dec 30, 2025); a wave of litigation notices increases legal and reputational risk and may pressure the stock. Representative alerts include Hagens Berman and Pomerantz. Article Title Article Title

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.